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Abstract
Background: Few data are available on long-term follow-up of DES in the treatment of chronic 
total occlusion (CTO). The LEADERS CTO sub-study compared the long-term results in CTO and 
non-CTO lesions of a Biolimus A9™-eluting stent (BES) with a sirolimus-eluting stent (SES).
Methods: Among 1,707 patients enrolled in the prospective, multi‐center, all-comers LEADERS 
trial, 81 with CTOs were treated with either a BES (n = 45) or a SES (n = 36). The primary 
endpoint was the occurrence of major adverse cardiac events (MACE): cardiac death, myocardial 
infarction (MI) and clinically-indicated target vessel revascularization (TVR).
Results: At 5 years, the rate of MACE was numerically higher in the CTO group than in the non-
CTO group (29.6% vs. 23.3%; p = 0.173), with a significant increase in the incidence of target 
lesion revascularization (TLR) (21.0 vs. 12.6; p = 0.033), but no difference in stent thrombosis 
(ST).
Patients with CTO receiving a BES demonstrated a lower incidence of MACE (22.2% vs. 38.9%; p 
= 0.147) with a significant reduction in TLR compared to patients receiving a SES (11.1% vs. 
33.3%, p = 0.0214) with an incidence similar to that observed in the non-CTO group treated with 
BES (11.6%). Definite ST at 5 years nearly halved in the BES group (4.4% vs. 8.3%, p = 0.478) 
with no ST in the BES group after the first year (0% vs. 8.3%, p for interaction = 0.009).
Conclusions: The use of a BES showed a reduction in MACE, TVR, TLR, and ST over time in the 
CTO subset with similar outcome as for non-CTO lesions.
Key words: chronic total occlusion, biodegradable eluting stent, percutaneous coronary 
interventions
Introduction
Revascularization of chronic total occlusion (CTO) is grossly underutilized in patients who 
undergo percutaneous coronary interventions (PCI) [1–3]. The initial success is lower and a high 
rate of re-occlusion burdened the initial experiences with balloon angioplasty and bare metal stents 
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[4, 5]. The introduction of new devices, such as dedicated guidewires, low profile balloons, or 
microcatheters [6] has increased the immediate success rate, however greater complexity of lesions 
treated may potentially exacerbate the risk. Drug-eluting stents (DES) have reduced restenosis and 
reocclusion when compared with bare metal stents (BMS) [7–11], but a recent publication of long-
term data still reports worse results than those expected in non-CTO lesions [12]. Although second 
generation DES have greater polymer biocompatibility and different mechanical properties than 
first generation paclitaxel- and sirolimus-eluting stents (PES and SES), there are few data on long-
term results obtained with these devices in patients with CTO [13, 14] and on the differences with 
non-CTO lesions or CTO lesions treated with first generation DES.
The LEADERS CTO sub-study is a post-hoc analysis of a randomized multicenter trial and 
was designed to compare the results after five years of follow-up of CTO lesions treated with a 
Biolimus A9-eluting stent with abluminal biodegradable polymer coating (BES) and a sirolimus-
eluting permanent polymer stent (SES).
Methods
Study design and population
LEADERS was a prospective, multi‐center, assessor‐blind, non‐inferiority trial involving ten 
European centers (Belgium, France, Germany [3 centers], Netherlands, Poland, Switzerland [2 
centers] and the United Kingdom), designed to compare the safety and efficacy of a BES with a 
biodegradable polymer (BioMatrix Flex™, Biosensors Europe SA, Morges, Switzerland) with a 
SES with durable polymer (Cypher® Select™, Cordis, Miami, USA) in a “real world, all-comers” 
patient population. The LEADERS trial study design is reported elsewhere [15]. The LEADERS 
trial was approved by all institutional Ethics Committees.
Unlike most other DES studies, chronic total occlusion was not an exclusion criterion. CTO 
subgroup analysis is a post-hoc analysis performed on the LEADERS data set. Patients were 
divided according to the presence or absence of pre-procedural CTO, based on the pre-procedure 
angiogram and technical details of the intervention. Patients with at least one treated CTO lesion 
were classified as treated CTO patients. CTO was defined as a 100% coronary artery occlusion, 
with thrombolysis in myocardial infarction (TIMI) flow grade equal to 0 and duration of minimum 
3 months. The occlusion duration was either angiographically proven or clinically estimated, 
according to the onset of symptoms or the timing of acute coronary events in the territory subtended
by the CTO artery.
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Angiography was analyzed at one core laboratory (Cardialysis, Rotterdam, The Netherlands) 
with the assessor blinded to the allocated stent.
Procedures and devices
Biolimus-eluting stents were available in diameters of 2.25, 2.5, 3.0, and 3.5 mm and in 
lengths of 8, 11, 14, 18, 24, and 28 mm. Sirolimus-eluting stents were available in diameters of 
2.25, 2.5, 2.75, 3.0, and 3.5 mm and in lengths of 8, 13, 18, 23, 28, and 33 mm. Both platforms are 
made of stainless steel but BES struts are thinner (120 μm) than SES struts (140 μm). The main 
difference is represented by the drug, i.e. biolimus A9 versus sirolimus, and polymer used, i.e. a 
biodegradable polylactic acid coating in the BES versus a durable polymer covering in the SES.
Balloon angioplasty and stent implantation were performed according to standard techniques. 
In the CTO group, either anterograde or retrograde recanalization strategies were allowed, no 
restrictions were applied to the material used. Full lesion coverage with the index stent was the 
routine strategy.
Before or at the time of the procedure, patients were given at least 75 mg of acetylsalicylic 
acid, 300–600 mg loading dose of clopidogrel, and unfractionated heparin in a dose of at least 5,000
IU or 70–100 IE/kg. The use of glycoprotein IIb/IIIa antagonists was left to the discretion of the 
operator.
All patients were discharged on at least 75 mg daily acetylsalicylic acid indefinitely and 
clopidogrel 75 mg daily for at least 12 months.
Outcomes
In-hospital adverse events were assessed and clinical follow-up was planned up to 5 years.
The primary endpoint was a composite of cardiac death, myocardial infarction (MI), and 
clinically indicated target vessel revascularization (TVR). The definition of cardiac death included 
any death due to immediate cardiac cause (e.g., MI, low-output failure, fatal arrhythmia), deaths 
related to the procedure, including those related to concomitant treatment, unwitnessed death, and 
death of unknown cause. MI was defined using the electrocardiographic criteria of the Minnesota 
code manual or as a measurement of creatine kinase concentrations to more than double normal, 
with positive concentrations of creatine kinase-MB or troponin I or T. TVR was defined as any 
repeat percutaneous intervention or surgical bypass of any segment within the entire major coronary
vessel proximal and distal to a target lesion, including upstream and downstream branches and the 
target lesion itself. Revascularization was regarded as clinically indicated if the stenosis of the 
treated lesion was at least 50% of the lumen diameter on the basis of quantitative coronary 
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angiography in the presence of ischemic signs or symptoms, or if the diameter stenosis was at least 
70% irrespective of the presence or absence of ischemic signs or symptoms.
Secondary endpoints were cardiac death, death from any cause, MI, clinically-indicated target
lesion revascularization (TLR) defined as a repeated revascularization due to a stenosis within the 
stent or within a 5 mm border proximal or distal to the stent, repeated PCI (re-PCI), any TVR, or 
stent thrombosis (ST) according to the definitions of the Academic Research Consortium [16].
Statistical Analysis
The statistical design of the LEADERS trial is described elsewhere [15].
A stratified post hoc analysis of clinical and angiographic outcomes was performed within the
treated CTO and non-CTO groups, with patients compared based on the randomized study stents 
(BES or SES) implanted.
Discrete data were summarized as frequencies (n. %) and compared by Fisher’s exact test. 
Continuous data were expressed as mean ± standard deviation and compared by Student’s t-test. 
The Cox proportional hazards model was used to compare clinical outcomes among groups. 
Survival curves were constructed for time-to-event variables using Kaplan-Meier estimates, and 
compared by the log-rank test. All p-value and confidence intervals are two-sided at 5% level.
Results
A total of 1,707 patients were enrolled in the LEADERS trial. Among them 86 had a CTO 
lesion, of which 81 patients were successfully treated with either the study or comparator stent (45 
patients with BES versus 36 patients with SES). The non-CTO group included 1,621 patients, of 
which 809 were treated with BES versus 812 with SES (Fig. 1).
Baseline characteristics
Baseline characteristics according to CTO and non-CTO group and type of stent implanted in 
each group are shown in Table 1.
There were no major baseline clinical differences between patients with and without CTOs, 
except for a greater frequency of STEMI in the non-CTO group and a higher incidence of prior MI 
in the CTO group.
Compared to non-CTO lesions, CTO lesions were significantly more complex as reflected by 
greater lesion length with a higher Syntax score, resulting in a greater number of stents implanted. 
Within the CTO group, there was a higher number of lesions treated in the SES group compared to 
the BES group (1.89 ± 1.04 vs. 1.44 ± 0.66; p = 0.029), as well as the syntax score (20.0 ± 8.6 vs. 
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15.2 ± 8.7; p = 0.048). No significant differences were found with regard to stent length and number
of stents implanted (Table 1).
Angiographic and procedural characteristics for the CTO group demonstrate that the right 
coronary artery was more frequently targeted in the BES group (Table 2).
CTO vs. non-CTO lesions
At 5-year follow-up, the incidence of overall MACE was similar between the CTO and non-
CTO groups (29.6% vs. 23.3%; p = 0.173). Likewise, no significant differences were found in the 
rate of cardiac death, MI and both clinically-indicated and any TVR (Table 3). Clinically-indicated 
TLR did not show any statistical significant difference in the CTO and non-CTO groups (16% vs. 
10.5%; p = 0.13), but the number of any TLR was significantly higher in the CTO group (Fig. 2, 
Panel A). The incidence of definite ST and definite plus probable ST was percentually higher, yet 
not significant in the CTO compared to non-CTO group (Table 3).
CTO lesions: BES vs. SES
Patients with CTO treated with BES had a non-significant lower incidence of MACE (22.2% 
vs. 38.9%; HR 0.549, 95% CI 0.243–1.236; p = 0.147). With regard to other clinical endpoints, such
as cardiac death, clinically-indicated TVR and TLR, the rate of events was numerically lower in the 
BES, while the percentage of MI was slightly higher (Table 3). The incidence of clinically-indicated
TLRs was halved in the BES group (11% vs. 22%; HR 0.468, 95% CI 0.153–1.433; p = 0.184). 
However, all TLRs had a significantly higher rate in the patients receiving a SES (Fig. 2, panel B). 
Of interest, in the long-term follow-up the rate of any TLR was similar between the BES CTO 
group and overall non-CTO group (11.1% vs. 12.6%). Moreover, the use of a BES in the CTO 
group reduced by almost two thirds the risk of any TVR (HR 0.326, 95% CI 0.113–0.942; p = 
0.038) and any repeated PCI (HR 0.350, 95% CI 0.141–0.870; p = 0.024).
The incidence of definite ST was nearly halved in the BES group (4.4% vs. 8.3%; HR 0.523, 
95% CI 0.087–3.132; p = 0.478). These results were also maintained regardless of dual antiplatelet 
therapy compliance (Table 4).
However, although BES had a higher rate of early (≤ 30 days) definite ST (4.4% vs. 0%), no 
events were recorded in the late and very late period. Definite ST occurred more frequently in the 
very late period for the SES (pfor interaction = 0.009). The same trend was also found in the 30 days 
landmark analysis for MACE, significantly lower between 30 days and 5 years in the BES group 
(pfor interaction = 0.042) (Fig. 3).
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Discussion
Patients with CTO are often denied angioplasty because the immediate success rate is lower 
than in conventional PCI [17, 18] and the long-term durability is questioned. Limited data are 
available for comparison of long-term follow-up in CTO and non-CTO patients. In the j-Cypher 
registry [19], 1,210 patients with CTO (defined as complete obstruction with TIMI flow grade 0 or 
1 and an estimated duration > 1 month) were compared to 9,549 patients who underwent PCI on a 
non-occlusive lesion or a recent occlusion. After five years of follow-up, the rate of TLR was 
significantly higher if a CTO lesion was treated. However, the incidence of all-cause death and 
cardiac death was similar between CTO and non-CTO patients. This study confirms the higher 
incidence of late events, especially TLR, in CTO patients treated with SES. The similar outcome 
observed in CTO and non-CTO groups treated with BES suggests that second generation DES 
should be preferred in these complex lesions to preserve the clinical benefit conferred by a 
successful CTO recanalization. Multiple registries have indicated that a restored patency of a 
complete occlusion may translate into a greater clinical benefit than treatment of other non-
occlusive lesions in stable syndromes [20–22]. ST, especially in the late and very late period, 
represents one of the main limitations of drug eluting stents [23–25]. In our study, the overall 
incidence of all ST and of definite ST was similar between the CTO and non-CTO groups. These 
data are in line with the findings of the j-Cypher registry where the definite/probable ST did not 
differ according to the groups. However, in that study, the only device employed was a SES.
In our study, we tested two different DES platforms, from polymers and type of drug eluted to
mechanical properties. In recent studies comparing first versus second generation DES for the 
treatment of CTOs [10–11], a favorable trend was observed for second generation DES in short-
term follow-up. These promising results were also confirmed by our study. In fact, in the CTO 
lesion subset, our data showed a notable reduction of events in favor of the biodegradable polymer 
Biolimus A9-coated stent with a higher reduction mainly in the long-term follow-up, equalizing the 
outcome between CTO and non-CTO groups.
This represents one of the main findings of our study. In fact, initial experiences in the 
POBA/BMS era showed that outcome of CTO was worse than non-CTO lesions [26]. This worse 
outcome was improved but not fully corrected by the introduction of first generation DES [27].
Several factors may explain these results. Sirolimus-eluting stents show histologic evidence of
poor biocompatibility with hypereosinophilic infiltrates [28] and slow incomplete strut coverage 
which has been confirmed with OCT [29]. Evaginations between struts are a quite specific feature 
of the Cypher stent and a 9-month OCT substudy of LEADERS was the first to show a difference in
strut coverage between BES and SES [30], with late catch-up shown at 2 years [31]. The rigidity 
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and great thickness of Cypher also predispose this stent to late fracture, often associated to 
restenosis and re-occlusion. CTO recanalization is associated with the frequent use of long stents in 
vessels with most treatments performed in the right coronary artery, a vessel characterized by large 
systo-diastolic excursions. A DES with a bioabsorbable polymer has the advantage of the polymer 
gradually degrading and eventually disappearing over the course of several months, limiting the risk
of the late thrombotic events in the durable polymer group, especially in complex lesions, such as 
the CTOs.
Limitation of the study
Our study has several limitations. First, the LEADERS CTO study, as a post-hoc analysis of a 
randomized controlled trial, was not powered to test the difference between CTO and non-CTO 
groups. Although the trial was undertaken in ten European centers where high volume PCI 
procedures were performed by experienced operators using modern approaches, patients with at 
least one CTO treated were less than 5% of all the lesions treated. The lack of sub-randomization 
for CTO explains some discrepancies in the basal characteristics of the SES and BES groups but the
fact lesions come from an all-comers registry improves homogeneity, making the groups more 
comparable and the selection process more rigorous than in other retrospective registries.
The main strength of this sub-study is represented by the confirmation of the type of lesion 
treated by an independent Core Lab, with nearly complete, well documented and fully monitored 
follow-up.
Conclusions
Chronic total occlusion subgroup of the LEADERS all-comers trial showed that BES may 
reduce at five-year follow-up MACE, TVR, TLR and stent thrombosis when compared to SES. For 
stent thrombosis, the benefit of DES with biodegradable polymer seems to emerge in the late and 
very late phase, after the polymer is fully degraded.
These results of the CTO group are consistent with the overall trial but tested in a small 
subgroup and a larger trial is needed to explore these hypotheses.
Moreover, our data suggest that patients with a successful recanalization of a CTO lesion with
BES may have similar outcome to patients without CTO treated with PCI, encouraging a more 
liberal use of PCI in CTOs.
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Table 1. Baseline characteristics. The groups are divided according to the type of revascularization 
and stent.
N (%) or mean ± SD
Treated CTO (n = 81) No CTO (n = 1621) P: Treated 
CTO vs. no 
CTO
BES (n 
= 45)
SES (n 
= 36)
P: BES
vs. SES
BES (n 
= 809)
SES (n 
= 812)
p-value
BES vs.
SES
Age [years] 62.0 ± 
10.5
64.9 ± 
12.4
0.264 64.7 ± 
10.8
64.5 ± 
10.6
0.658 0.277
Male 38 (84.4) 27 (75.0) 0.401 602 (74.4) 605 (74.5) 1 0.294
Diabetes 12 (26.7) 5 (13.9) 0.182 210 (26.0) 185 (22.8) 0.148 0.595
Hypertension 28 (62.2) 27 (75.0) 0.242 600 (74.3) 589 (72.7) 0.499 0.303
Hypercholesterolemia 36 (80.0) 27 (75.0) 0.603 522 (64.6) 552 (68.1) 0.141 0.039
Currently smoking 9 (20.0) 9 (25.0) 0.603 195 (24.1) 205 (25.3) 0.604 0.693
Family history 22 (48.9) 19 (52.8) 0.824 316 (39.1) 355 (43.8) 0.055 0.107
Unstable angina 5 (11.1) 5 (13.9) 0.745 185 (22.9) 175 (21.6) 0.550 0.038
STEMI 0 (0) 1 (2.8) 0.444 135 (16.7) 139 (17.1) 0.843 < 0.001
Chronic heart failure 3 (6.7) 1 (2.8) 0.625 20 (2.5) 29 (3.6) 0.246 0.316
Prior MI 24 (53.3) 17 (47.2) 0.658 251 (31.1) 259 (32.0) 0.708 < 0.001
Prior PCI 18 (40.0) 10 (27.8) 0.347 294 (36.4) 300 (37.0) 0.797 0.725
Prior CABG 5 (11.1) 7 (19.4) 0.354 85 (10.5) 100 (12.3) 0.274 0.372
LV ejection fraction [%] 52.8 ± 
12.7
57.6 ± 
12.9
0.250 56.0 ± 
11.2
55.3 ± 
12.4
0.360 0.613
Multivessel disease 14 (31.1) 12 (33.3) 1 192 (23.7) 164 (20.2) 0.093 0.040
Number of lesions* 1.44 ± 
0.66
1.89 ± 
1.04
0.029 1.46 ± 
0.69
1.41 ± 
0.70
0.113 0.037
Lesions length† [mm] 45.4 ± 
24.9
44.4 ± 
23.1
0.843 21.0 ± 
15.0
19.5 ± 
13.5
0.029 < 0.001
Long lesion (> 20 mm) 35 (79.6) 27 (77.1) 1 223 (27.8) 192 (23.9) 0.087 < 0.001
Severe calcification 5 (17.9) 7 (28.0) 0.514 141 (20.8) 147 (22.0) 0.595 0.865
Syntax score 15.2 ± 8.7 20.0 ± 8.6 0.048 13.2 ± 8.6 13.1 ± 8.7 0.819 < 0.001
Number of stents implanted 
per patient‡
2.96 ± 
1.46
3.14 ± 
1.64
0.597 1.90 ± 
1.20
1.80 ± 
1.09
0.081 < 0.001
Total stent length [mm] 65.5 ± 
37.0
68.0 ± 
35.6
0.945 34.2 ± 
22.1
33.3 ± 
20.6
0.440 < 0.001
*Number of lesions according to Core Lab (QCA data), regardless if they were total occluded pre-
procedure; †Sum of the length of the lesions according to QCA analysis, regardless if they were total
occluded; ‡Investigator reported per lesion the number of stents and the stent length per used stent. 
The total number of stents and total stent length per patient is calculated, regardless if the lesions 
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were total occluded pre-procedure; BES — biodegradable eluting stent; CTO — chronic total 
occlusion; SD — standard deviation; SES — sirolimus-eluting stent
14
Table 2. Procedural and angiographic characteristics in the CTO group.
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N (%) or mean ± SD
BES (n = 45) SES (n = 36) P: BES vs. 
SES
CTO lesion coronary 
artery
Left main 0 (0) 0 (0) NA
Left anterior descending 15 (33.3) 13 (36.1) 0.818
Left circumflex 7 (15.6) 12 (33.3) 0.071
Right coronary artery 23 (51.1) 9 (25.0) 0.023
Bypass graft 0 (0) 2 (5.6) 0.194
Presence of stump 27 (60) 17 (47.2) 0.251
Bridging collateral 14 (31.1) 9 (25.0) 0.544
Retrograde filling 23 (51.1) 21 (58.3) 0.517
Anterograde approach 44 (97.8) 36 (100) NA
Bilateral Injection 10 (22.2) 9 (25.0) 0.769
Number of stents 
implanted
2.36 ± 1.40 2.00 ± 1.01 0.205
Total stent length [mm] 55.5 ± 34.6 46.3 ± 25.3 0.194
RVD [mm]
In-stent 2.63 ± 0.53 2.59 ± 0.45 0.751
In-segment 2.54 ± 0.58 2.46 ± 0.49 0.501
MLD post-procedure 
[mm]
In-stent 2.10 ± 0.66 2.11 ±0.53 0.985
In-segment 1.79 ± 0.62 1.78 ±0.58 0.944
MLA post procedure 
[mm2]
In-stent 3.59 ± 1.87 3.37 ± 1.58 0.585
In-segment 2.66 ± 1.58 2.54 ± 1.53 0.730
CTO — chronic total occlusion; SD — standard deviation; BES — biodegradable eluting stent; 
SES — sirolimus-eluting stent
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Table 3. Events at 5-year follow-up.
N (%)
Treated CTO 
(n = 81)
No CTO
(n = 1621)
P: 
ALL
Treat
ed 
CTO 
vs. No
CTO
All (n = 81) BES 
(n = 
45)
SES 
(n = 
36) 
Hazard ratio
[95% CI]
(BES vs. 
SES)
P: 
BES 
vs. 
SES
All (n 
= 
1621)
BES 
(n = 
809)
SES 
(n = 
812)
Hazard ratio 
[95% CI]
(BES vs. 
SES)
P: 
BES 
vs. 
SES
MACE
24 (29.6)
10 
(22.2)
14 
(38.9)
0.549 [0.243–
1.236]
0.147
377 
(23.3)
175 
(21.6)
202 
(24.9)
0.850 [0.694–
1.040]
0.115 0.173
Cardiac death 6 (7.4) 2 (4.4) 4 (11.1) 0.384 [0.070–
2.097]
0.269 129 (8.0) 64 (7.9) 65 (8.0) 0.981 [0.695–
1.385]
0.913 0.819
MI (Q-wave + 
non-Q-wave)
10 (12.3) 6 (13.3) 4 (11.1) 1.228 [0.346–
4.353]
0.751 155 (9.6) 75 (9.3) 80 (9.9) 0.931 [0.679–
1.276]
0.656 0.408
Clinical TVR 14 (17.3) 5 (11.1) 9 (25.0) 0.411 [0.138–
1.229]
0.112 214 
(13.2)
99 
(12.2)
115 
(14.2)
0.845 [0.646–
1.106]
0.220 0.303
MI      
Q-wave MI 0 (0.0) 0 (0.0) 0 (0.0) NA NA 24 (1.5) 8 (1.0) 16 (2.0) 0.496 [0.212–
1.158]
0.105 NA
Non-Q-wave 
MI
10 (12.3) 6 (13.3) 4 (11.1) 1.228 [0.346–
4.353]
0.751 135 (8.3) 67 (8.3) 68 (8.4) 0.982 [0.701–
1.377]
0.918 0.208
All death      
All death 10 (12.3) 5 (11.1) 5 (13.9) 0.760 [0.220–
2.625]
0.664 205 
(12.6)
97 
(12.0)
108 
(13.3)
0.895 [0.680–
1.177]
0.426 0.882
Revascularizati
on
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N (%)
Treated CTO 
(n = 81)
No CTO
(n = 1621)
P: 
ALL
Treat
ed 
CTO 
vs. No
All (n = 81) BES 
(n = 
45)
SES 
(n = 
36) 
Hazard ratio
[95% CI]
(BES vs. 
SES)
P: 
BES 
vs. 
SES
All (n 
= 
1621)
BES 
(n = 
809)
SES 
(n = 
812)
Hazard ratio 
[95% CI]
(BES vs. 
SES)
P: 
BES 
vs. 
SES
All clinical TLR 13 (16.0) 5 (11.1) 8 (22.2) 0.468 [0.153–
1.433]
0.184 171 
(10.5)
78 (9.6) 93 
(11.5)
0.827 [0.612–
1.118]
0.217 0.130
PCI 12 (14.8) 5 (11.1) 7 (19.4) 0.544 [0.173–
1.717]
0.299 156 (9.6) 71 (8.8) 85 
(10.5)
0.826 [0.602––
1.132]
0.234 0.135
CABG 2 (2.5) 0 (0.0) 2 (5.6) NA NA 24 (1.5) 11 (1.4) 13 (1.6) 0.846 [0.379–
1.889]
0.684 0.506
Any TLR 17 (21.0) 5 (11.1) 12 
(33.3)
0.293 [0.103–
0.833]
0.0214 204 
(12.6)
94 
(11.6)
110 
(13.5)
0.843 [0.640–
1.110]
0.225 0.033
Any TVR 16 (19.8) 5 (11.1) 11 
(30.6)
0.326 [0.113–
0.942]
0.038 232 
(14.3)
108 
(13.3)
124 
(15.3)
0.858 [0.663–
1.110]
0.244 0.178
Any re-PCI 21 (25.9) 7 (15.6) 14 
(38.9)
0.350 [0.141–
0.870]
0.024 394 
(24.3)
187 
(23.1)
207 
(25.5)
0.884 [0.725–
1.077]
0.221 0.762
Definite ST 5 (6.2) 2 (4.4) 3 (8.3) 0.523 [0.087–
3.132]
0.478 53 (3.3) 20 (2.5) 33 (4.1) 0.603 [0.346–
1.050]
0.074 0.177
Definite + 
Probable ST
5 (6.2) 2 (4.4) 3 (8.3) 0.523 [0.087–
3.132]
0.478 70 (4.3) 29 (3.6) 41 (5.0) 0.704 [0.438–
1.133]
0.148 0.447
Acute (0 to 1 
days)
     
Definite ST 1 (1.2) 1 (2.2) 0 (0.0) NA NA 11 (0.7) 7 (0.9) 4 (0.5) 1.757 [0.514–
6.003]
0.368 0.566
Definite or 
Probable ST
1 (1.2) 1 (2.2) 0 (0.0) NA NA 11 (0.7) 7 (0.9) 4 (0.5) 1.757 [0.514–
6.003]
0.368 0.566
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N (%)
Treated CTO 
(n = 81)
No CTO
(n = 1621)
P: 
ALL
Treat
ed 
CTO 
vs. No
All (n = 81) BES 
(n = 
45)
SES 
(n = 
36) 
Hazard ratio
[95% CI]
(BES vs. 
SES)
P: 
BES 
vs. 
SES
All (n 
= 
1621)
BES 
(n = 
809)
SES 
(n = 
812)
Hazard ratio 
[95% CI]
(BES vs. 
SES)
P: 
BES 
vs. 
SES
Sub-Acute (2 to 
30 days)
     
Definite ST 1 (1.2) 1 (2.2) 0 (0.0) NA NA 16 (1.0) 5 (0.6) 11 (1.4) 0.454 [0.158–
1.306]
0.143 0.835
Definite or 
Probable ST
1 (1.2) 1 (2.2) 0 (0.0) NA NA. 22 (1.4) 9 (1.1) 13 (1.6) 0.691 [0.295–
1.616]
0.394 0.919
Early (0 to 30 
days)
     
Definite ST 2 (2.5) 2 (4.4) 0 (0.0) NA NA 26 (1.6) 12 (1.5) 14 (1.7) 0.860 [0.398–
1.859]
0.701 0.558
Definite or 
Probable ST
2 (2.5) 2 (4.4) 0 (0.0) NA NA 32 (2.0) 16 (2.0) 16 (2.0) 1.003 [0.502–
2.005]
0.994 0.761
Late (31 to 360 
days)
     
Definite ST 0 (0.0) 0 (0.0) 0 (0.0) NA NA 7 (0.4) 3 (0.4) 4 (0.5) 0.754 [0.169–
3.367]
0.711 n.a.
Definite or 
Probable ST
0 (0.0) 0 (0.0) 0 (0.0) NA NA 9 (0.6) 5 (0.6) 4 (0.5) 1.257 [0.338–
4.681]
0.733 n.a.
Very late (361 
to 1800 days)
     
Definite ST 3 (3.7) 0 (0.0) 3 (8.3) NA NA 21 (1.3) 5 (0.6) 16 (2.0) 0.308 [0.113–
0.842]
0.022 0.093
Definite or 
probable ST
3 (3.7) 0 (0.0) 3 (8.3) NA NA 30 (1.9) 8 (1.0) 22 (2.7) 0.359 [0.160–
0.807]
0.013 0.262
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BES — biodegradable eluting stent; CABG — coronary artery bypass graft; CI — confidence interval; CTO — chronic total occlusion; MACE — 
major adverse cardiac events; MI — myocardial infarction; PCI — percutaneous coronary interventions; SES — sirolimus-eluting permanent 
polymer stent; ST — stent thrombosis; TLR — target lesion revascularization; TVR — target vessel revascularization
Table 4. All stent thrombosis (ST) and dual antiplatelet (DAPT) discontinuation (d/c) for chronic total occlusion (CTO) patients.
N (%) BES (n = 45) SES (n = 36)
P: BES vs. 
SES*
Overall population†
 9 months 2 (4.4) 0 (0) 0.500
 1 year 2 (4.4) 0 (0) 0.500
 2 years 2 (4.4) 2 (5.6) 1
 3 years 2 (4.4) 3 (8.3) 0.651
 4 years 2 (4.4) 3 (8.3) 0.651
 5 years 2 (4.4) 3 (8.3) 0.651
BES (n = 10) SES (n = 11)
Patients who d/c DAPT < 12 
months‡
 9 months 0 (0) 0 (0) NA
 1 year 0 (0) 0 (0) NA
 2 years 0 (0) 1 (9.1) 1
 3 years 0 (0) 2 (18.2) 0.476
 4 years 0 (0) 2 (18.2) 0.476
 5 years 0 (0) 2 (18.2) 0.476
BES (n = 31) SES (n = 23)
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N (%) BES (n = 45) SES (n = 36)
P: BES vs. 
SES*
Patients who d/c DAPT ≥ 12 
months‡
 9 months 0 (0) 0 (0) NA
 1 year 0 (0) 0 (0) NA
 2 years 0 (0) 1 (4.3) 0.426
 3 years 0 (0) 1 (4.3) 0.426
 4 years 0 (0) 1 (4.3) 0.426
 5 years 0 (0) 1 (4.3) 0.426
*Fisher’s exact test; †All ST are reported, regardless if patient discontinued DAPT and if the ST took place before or after d/c DAPT; ‡Only reported
if the ST took place after date of d/c DAPT; BES — biodegradable eluting stent; SES — sirolimus-eluting stent
21
Figure 1. Study flow chart; BES — biodegradable eluting stent; CTO — chronic total occlusion; SES — sirolimus-eluting stent.
Figure 2. A. Kaplan-Meier curves show the incidence of target lesion revascularization (TLR) in chronic total occlusion (CTO) group vs. non-CTO 
group; B. Kaplan-Meier curves show the incidence of TLR within the CTO group between biodegradable eluting and sirolimus-eluting stents; HR 
22
— hazard ratio; CI — confidence interval.
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Figure 3. Landmark analysis at 30 days for major adverse cardiac events (MACE); BES — biodegradable eluting stent; CI — confidence interval; 
HR — hazard ratio; SES — sirolimus-eluting stent.
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